Laura Gault
Chief Tech/Sci/R&D Officer bei SAGE THERAPEUTICS, INC.
Vermögen: 215 079 $ am 31.03.2024
Profil
Laura Gault is currently the Chief Medical Officer at SAGE Therapeutics, Inc. Prior to her current position, she worked as the Vice President at Alexion Pharmaceuticals, Inc. from 2019 to 2022 and as the Vice President-Neurology Clinic Development at Vertex Pharmaceuticals, Inc. from 2017 to 2019.
Gault received her undergraduate degree from the University of Pittsburgh and her doctorate from Case Western Reserve University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SAGE THERAPEUTICS, INC.
0,02% | 13.02.2024 | 11 477 ( 0,02% ) | 215 079 $ | 31.03.2024 |
Aktive Positionen von Laura Gault
| Unternehmen | Position | Beginn |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31.10.2022 |
Ehemalige bekannte Positionen von Laura Gault
| Unternehmen | Position | Ende |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.11.2022 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.03.2019 |
Ausbildung von Laura Gault
| University of Pittsburgh | Undergraduate Degree |
| Case Western Reserve University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| SAGE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
